<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10787">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625131</url>
  </required_header>
  <id_info>
    <org_study_id>NEUA-007-07F</org_study_id>
    <nct_id>NCT00625131</nct_id>
  </id_info>
  <brief_title>Nicotine Patch Pretreatment for Smoking Cessation in PTSD</brief_title>
  <official_title>Nicotine Patch Pre-treatment for Smoking Cessation in PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the relationship between PTSD, abstinence, and factors
      associated with relapse in the context of a randomized, clinical smoking cessation trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smokers with PTSD will be randomly assigned to 1 of 2 pre-cessation patch therapy conditions
      (active patch versus placebo patch) for three weeks before a target quit-smoking date. All
      participants to will receive bupropion beginning 1 week prior to their quit day, given that
      they are medically eligible to be prescribed bupropion. All participants will receive a two
      session brief cognitive-behavioral therapy (CBT) session and will begin standard nicotine
      replacement therapy (NRT) on their quit day. PTSD symptoms, mood, and smoking craving will
      be carefully evaluated throughout the study using electronic diary assessments on personal
      digital assistants (PDA). Specifically, participants will carefully monitor their symptoms,
      mood, craving, and use of cigarettes using electronic diaries for one week prior to the
      pre-cessation period, during the 3-week pre-cessation treatment period, and 6 weeks post
      quit date. Since no previous study has examined factors associated with smoking abstinence
      following treatment among PTSD smokers10, predictors of treatment response will be examined.
      The study is designed to address the following items:

      Specific Aim 1: To evaluate whether supplemental nicotine administration (i.e.,
      pre-cessation treatment with nicotine patch and bupropion) will result in improved quit
      rates among smokers with PTSD.

      Hypothesis 1.1 Supplemental nicotine administration during the pre-cessation period will
      result in improved quit rates in the first quit week over the placebo patch condition.

      Specific Aim 2: To utilize electronic diary assessment of PTSD symptoms, mood, smoking
      craving, and smoking during baseline, pretreatment, and quit periods to evaluate potential
      mechanisms of how pretreatment with the nicotine patch may increase abstinence rates.

      Hypothesis 2.1 Supplemental nicotine administration will decrease craving for cigarettes
      during the 2 week pretreatment period as compared to the placebo patch condition.

      Hypothesis 2.2 Supplemental nicotine administration will decrease the perceived improvement
      in mood and PTSD symptoms associated with smoking behavior, i.e., symptom relief from ad lib
      smoking a cigarette will be reduced during supplemental nicotine administration as compared
      to the placebo patch condition.

      Specific Aim 3: To investigate potential predictors of smoking abstinence and relapse
      associated with individual differences in affective style including anxiety sensitivity,
      measures of distress tolerance, and self-efficacy.

      Hypothesis 3.1 Increased anxiety sensitivity will be predictive of shorter abstinence from
      smoking.

      Hypothesis 3.2 Decreased distress tolerance will be predictive of shorter abstinence.

      Hypothesis 3.3 Lower self-efficacy for smoking abstinence will be predictive of shorter
      abstinence.

      Hypothesis 3.4 Increased PTSD symptoms severity and negative affect following the quit date
      will be associated with shorter abstinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Smoking Abstinence, Self-reported</measure>
    <time_frame>Week prior to Session 12 at 6 weeks post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carbon Monoxide Monitoring</measure>
    <time_frame>Session 12 (6 weeks post-treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants whose carbon monoxide (CO) measurement indicated abstinence at Session 12 (6 weeks post-treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Craving</measure>
    <time_frame>Daily between visits 2-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean smoking craving score (as measured during daily ecological momentary, or diary, assessments) for participants by group during the two week period of placebo/active pre-treatment. This is the main period of interest, as it was hypothesized that use of active nicotine patch would reduce smoking cravings during the pre-quit period. The craving score is based on a single diary item &quot;Please rate your desire to smoke right now&quot; with a Likert scale score ranging from 1 (none) to 5 (severe). Higher craving is &quot;worse,&quot; as lower craving is presumed to reflect decreased risk of smoking lapse or relapse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Stress Disorders, Posttraumatic</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Active Nicotine Patch Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transdermal nicotine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Patch Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Transdermal placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Delivered through transdermal nicotine patch</description>
    <arm_group_label>Active Nicotine Patch Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy for Smoking Cessation</intervention_name>
    <description>Manualized protocol for CBT in smoking cessation</description>
    <arm_group_label>Active Nicotine Patch Group</arm_group_label>
    <arm_group_label>Placebo Patch Group</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion Sustained Release (SR)</intervention_name>
    <description>Antidepressant</description>
    <arm_group_label>Active Nicotine Patch Group</arm_group_label>
    <arm_group_label>Placebo Patch Group</arm_group_label>
    <other_name>Zyban, Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>Pre-treatment placebo transdermal patch</description>
    <arm_group_label>Placebo Patch Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smokers who smoke 10 or more cigarettes per day in the past year;

          -  18-80 years old;

          -  English speakers;

          -  medically stable;

          -  stable on current medication regimen

        Exclusion Criteria:

          -  Pregnant women excluded;

          -  participants with organic mental disorder, schizophrenia, bipolar disorder, lifetime
             but not current PTSD, current substance abuse or dependence;

          -  medical conditions contraindicated with nicotine replacement therapy;

          -  use other forms of nicotine (cigars, nicotine gum, etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean C. Beckham, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Durham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Durham</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 12, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2008</firstreceived_date>
  <firstreceived_results_date>October 28, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stress Disorders, Posttraumatic</keyword>
  <keyword>Tobacco Use Disorder</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Nicotine Patch Group</title>
          <description>Transdermal nicotine patch
Nicotine: Delivered through transdermal nicotine patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
        </group>
        <group group_id="P2">
          <title>Placebo Patch Group</title>
          <description>Transdermal placebo patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
        </group>
        <group group_id="P3">
          <title>Not Randomized</title>
          <description>This arm includes patients who met screening criteria for entry into the randomization, but withdrew prior to randomization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="5">These participants were not included in any analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Transdermal nicotine patch
Nicotine: Delivered through transdermal nicotine patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Transdermal placebo patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.16" spread="9.61"/>
                <measurement group_id="B2" value="44.48" spread="11.31"/>
                <measurement group_id="B3" value="44.79" spread="10.51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="79"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Smoking Abstinence, Self-reported</title>
        <description>Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment</description>
        <time_frame>Week prior to Session 12 at 6 weeks post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Any participants who did not attend Session 12 for any reason (i.e., lost to contact, withdrawn after beginning treatment) were counted as smoking (i.e., intent-to-treat analyses, missing = smoking).</population>
        <group_list>
          <group group_id="O1">
            <title>Active Nicotine Patch Group</title>
            <description>Transdermal nicotine patch
Nicotine: Delivered through transdermal nicotine patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
          </group>
          <group group_id="O2">
            <title>Placebo Patch Group</title>
            <description>Transdermal placebo patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Smoking Abstinence, Self-reported</title>
            <description>Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carbon Monoxide Monitoring</title>
        <description>Number of participants whose carbon monoxide (CO) measurement indicated abstinence at Session 12 (6 weeks post-treatment)</description>
        <time_frame>Session 12 (6 weeks post-treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Please note that this secondary outcome (bioverification by CO reading) is not a measure of complete smoking abstinence during the study period (or during the week prior to the session - see Primary Outcome). It is independent of self-reported smoking abstinence. It is not unexpected that CO readings different than self-reported smoking.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Nicotine Patch Group</title>
            <description>Transdermal nicotine patch
Nicotine: Delivered through transdermal nicotine patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
          </group>
          <group group_id="O2">
            <title>Placebo Patch Group</title>
            <description>Transdermal placebo patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Carbon Monoxide Monitoring</title>
            <description>Number of participants whose carbon monoxide (CO) measurement indicated abstinence at Session 12 (6 weeks post-treatment)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Craving</title>
        <description>Mean smoking craving score (as measured during daily ecological momentary, or diary, assessments) for participants by group during the two week period of placebo/active pre-treatment. This is the main period of interest, as it was hypothesized that use of active nicotine patch would reduce smoking cravings during the pre-quit period. The craving score is based on a single diary item &quot;Please rate your desire to smoke right now&quot; with a Likert scale score ranging from 1 (none) to 5 (severe). Higher craving is &quot;worse,&quot; as lower craving is presumed to reflect decreased risk of smoking lapse or relapse.</description>
        <time_frame>Daily between visits 2-12</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Active Nicotine Patch Group</title>
            <description>Transdermal nicotine patch
Nicotine: Delivered through transdermal nicotine patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
          </group>
          <group group_id="O2">
            <title>Placebo Patch Group</title>
            <description>Transdermal placebo patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Smoking Craving</title>
            <description>Mean smoking craving score (as measured during daily ecological momentary, or diary, assessments) for participants by group during the two week period of placebo/active pre-treatment. This is the main period of interest, as it was hypothesized that use of active nicotine patch would reduce smoking cravings during the pre-quit period. The craving score is based on a single diary item &quot;Please rate your desire to smoke right now&quot; with a Likert scale score ranging from 1 (none) to 5 (severe). Higher craving is &quot;worse,&quot; as lower craving is presumed to reflect decreased risk of smoking lapse or relapse.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.48" spread="1.40"/>
                  <measurement group_id="O2" value="2.59" spread="1.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were collected in real time during each participant session or contact from baseline to 6 month follow-up (ranging from one day to nine months). These data represent AEs reported by all participants over the entire 4 years of data collection.</time_frame>
      <desc>Serious AEs were reviewed with the PI immediately after they were reported to the study coordinator. Non-serious AEs were reviewed with the PI at weekly staff meetings.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Nicotine Patch Group</title>
          <description>Transdermal nicotine patch
Nicotine: Delivered through transdermal nicotine patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
        </group>
        <group group_id="E2">
          <title>Placebo Patch Group</title>
          <description>Transdermal placebo patch
Cognitive Behavioral Therapy for Smoking Cessation: Manualized protocol for CBT in smoking cessation
Bupropion SR: Antidepressant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for preexisting circulatory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for pre-existing Chronic Obstructive Pulmonary Disease (COPD)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Gas and/or hemorrhoid pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Surgical Intervention, non-study related</sub_title>
                <description>Several participants had minor surgical interventions during the course of the study that were not related to study participation.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Orthopedic accident, not study related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of pre-existing PTSD symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sleep disturbance and/or increased nightmares</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching and/or skin rash at site of patch placement</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Kirby, MS; Regulatory Coordinator</name_or_title>
      <organization>VA Medical Center, Durham, NC</organization>
      <phone>9192860411 ext 5526</phone>
      <email>angela.kirby@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
